Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 405071, 6 pages
http://dx.doi.org/10.1155/2014/405071
Research Article

Quercetin Significantly Inhibits the Metabolism of Caffeine, a Substrate of Cytochrome P450 1A2 Unrelated to   (−2964G>A) and (734C>A) Gene Polymorphisms

1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
2Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
3Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, 110 Xiangya Road, Changsha, Hunan 410078, China

Received 17 March 2014; Revised 14 May 2014; Accepted 28 May 2014; Published 15 June 2014

Academic Editor: Daniela Parolaro

Copyright © 2014 Jian Xiao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. S. Fasinu, P. J. Bouic, and B. Rosenkranz, “An overview of the evidence and mechanisms of herb-drug interactions,” Frontiers in Pharmacology, vol. 3, article 69, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. L.-X. Wu, C.-X. Guo, W.-Q. Chen et al., “Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment,” British Journal of Clinical Pharmacology, vol. 73, no. 5, pp. 750–757, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. J.-S. Choi, Y.-J. Piao, and K. W. Kang, “Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin,” Archives of Pharmacal Research, vol. 34, no. 4, pp. 607–613, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. S. N. Umathe, P. V. Dixit, V. kumar, K. U. Bansod, and M. M. Wanjari, “Quercetin pretreatment increases the bioavailability of pioglitazone in rats: involvement of CYP3A inhibition,” Biochemical Pharmacology, vol. 75, no. 8, pp. 1670–1676, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J.-S. Choi and X. Li, “Enhanced diltiazem bioavailability after oral administration of diltiazem with quercetin to rabbits,” International Journal of Pharmaceutics, vol. 297, no. 1-2, pp. 1–8, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Dupuy, G. Larrieu, J. F. Sutra, A. Lespine, and M. Alvinerie, “Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin,” Veterinary Parasitology, vol. 112, no. 4, pp. 337–347, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Pavanello, U. Fedeli, G. Mastrangelo et al., “Role of CYP1A2 polymorphisms on lung cancer risk in a prospective study,” Cancer Genetics, vol. 205, no. 6, pp. 278–284, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. S.-L. Yeh and S.-H. Wu, “Effects of quercetin on β-apo-8′-carotenal-induced DNA damage and cytochrome P1A2 expression in A549 cells,” Chemico-Biological Interactions, vol. 163, no. 3, pp. 199–206, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. J. R. Bacon, G. Williamson, R. C. Garner, G. Lappin, S. Langouet, and Y. Bao, “Sulforaphane and quercetin modulate PhIP-DNA adduct formation in human HepG2 cells and hepatocytes,” Carcinogenesis, vol. 24, no. 12, pp. 1903–1911, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Chen, P. Xiao, D.-S. Ou-Yang et al., “Simultaneous action of the flavonoid quercetin on cytochrome p450 (cyp) 1a2, cyp2a6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers,” Clinical and Experimental Pharmacology and Physiology, vol. 36, no. 8, pp. 828–833, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. X.-M. Han, D.-S. Ou-Yang, P.-X. Lu et al., “Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2,” Pharmacogenetics, vol. 11, no. 5, pp. 429–435, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Butler, N. P. Lang, J. F. Young et al., “Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites,” Pharmacogenetics, vol. 2, no. 3, pp. 116–127, 1992. View at Google Scholar · View at Scopus
  13. D. M. Grant, B. K. Tang, and W. Kalow, “Variability in caffeine metabolism,” Clinical Pharmacology and Therapeutics, vol. 33, no. 5, pp. 591–602, 1983. View at Google Scholar · View at Scopus
  14. R. V. Priyadarsini and S. Nagini, “Quercetin suppresses cytochrome P450 mediated ROS generation and NFκB activation to inhibit the development of 7,12-dimethylbenz[a]anthracene (DMBA) induced hamster buccal pouch carcinomas,” Free Radical Research, vol. 46, no. 1, pp. 41–49, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. I.-H. Kang, H.-J. Kim, H. Oh, Y. I. Park, and M.-S. Dong, “Biphasic effects of the flavonoids quercetin and naringenin on the metabolic activation of 2-amino-3,5-dimethylimidazo[4,5-f]quinoline by Salmonella typhimurium TA1538 co-expressing human cytochrome P450 1A2, NADPH-cytochrome P450 reductase, and cytochrome b5,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 545, no. 1-2, pp. 37–47, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. C.-P. Yu, P.-P. Wu, Y.-C. Hou et al., “Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4,” Journal of Agricultural and Food Chemistry, vol. 59, no. 9, pp. 4644–4648, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. X. Li and J. S. Choi, “Effects of quercetin on the pharmacokinetics of etoposide after oral or intravenous administration of etoposide in rats,” Anticancer Research, vol. 29, no. 4, pp. 1411–1415, 2009. View at Google Scholar
  18. W. Tassaneeyakul, D. J. Birkett, M. E. Veronese et al., “Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2,” Journal of Pharmacology and Experimental Therapeutics, vol. 265, no. 1, pp. 401–407, 1993. View at Google Scholar · View at Scopus